Vaylen vs Sesame Care
Two GLP-1 desks, one scoreboard. We put Vaylen and Sesame Care head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Too close to call on the Brief Score.
Vaylen and Sesame Care are level at 87/100. The scores won't separate them, so the pick comes down to fit: Vaylen for readers who want brand, compounded and oral options from one accredited nationwide desk without a premium sticker. Sesame Care for shoppers who want genuine fda-approved brand-name glp-1s and the ability to pick their own provider and see the price up front, rather than one fixed compounded program.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Vaylen | Sesame Care | |
|---|---|---|
| Brief Score | 87/100 (B+) | 87/100 (B+) |
| Semaglutide | $179/mo | From $149/mo (brand Wegovy pill) |
| Tirzepatide | $239/mo | Brand Zepbound (price varies) |
| Coverage | All 50 states | Nationwide marketplace |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
Vaylen: $179 sema / $239 tirz; brand + oral + LegitScript across all 50 states.
Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.